• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomarin Pharmaceuticals (NQ: BMRN )

    66.60 +0.71 (+1.08%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,644,395
    Open 65.70
    Bid (Size) 65.80 (1)
    Ask (Size) 67.56 (1)
    Prev. Close 65.89
    Today's Range 65.60 - 66.81
    52wk Range 65.35 - 99.56
    Shares Outstanding 183,352,255
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth
    BioMarin posts Q3 EPS of $0.91, nearly doubling last year's $0.46 and topping estimates. Sales rose 28%, driven by strong Voxzogo growth. Analyst downgrades on lack of upcoming catalysts. 
    Via Benzinga
    In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical
    Via Benzinga

    Performance

    YTD
    -32.08%
    -32.08%
    1 Month
    -2.29%
    -2.29%
    3 Month
    -17.24%
    -17.24%
    6 Month
    -18.88%
    -18.88%
    1 Year
    -16.32%
    -16.32%

    More News

    Read More
    A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast
    Via Benzinga
    Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
    From Monopar Therapeutics Inc.
    Via GlobeNewswire
    Investors seeking growth at a reasonable cost should explore NASDAQ:BMRN.
    Via Chartmill
    How Is The Market Feeling About Biomarin Pharmaceutical?
    Via Benzinga
    Analyst Expectations For Biomarin Pharmaceutical's Future
    Via Benzinga
    If You Invested $1000 In This Stock 20 Years Ago, You Would Have $14,000 Today
    Via Benzinga
    NASDAQ:BMRN appears to be flying under the radar despite its strong fundamentals.
    Via Chartmill
    Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
    Via Benzinga
    3 Oversold Stocks with Big RSI Rebound Potential
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Investors should take note of NASDAQ:BMRN, a growth stock that remains attractively priced.
    Via Chartmill
    BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish
    Via Benzinga
    (BMRN) - Analyzing Biomarin Pharmaceutical's Short Interest
    Via Benzinga
    Investors should take notice of NASDAQ:BMRN—it offers a great deal for the fundamentals it presents.
    Via Chartmill
    Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
    Via Benzinga
    GE Vernova To Rally Over 30%? Here Are 10 Top Analyst Forecasts For Tuesday
    Via Benzinga
    Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term
    Via Benzinga
    Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug
    Via Investor's Business Daily
    FDA Battles Backlog of Drug Factory Inspections Since COVID-19
    Via Benzinga
    Exposures Product Safety
    BioMarin Restructures, Outlines Roadmap To $4B Revenues By 2027
    Via Benzinga
    Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (14 Ratings)
    Via Benzinga
    Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
    Via Benzinga
    NASDAQ:BMRN is showing good growth, while it is not too expensive.
    Via Chartmill
    Wall Street's Top 10 Stock Calls This Week - Saturday, Aug. 24
    Via Talk Markets
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.